Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

Landgren O., Weisel K., Rosinol L., Touzeau C., Turgut M., Hajek R., ...Daha Fazla

BRITISH JOURNAL OF HAEMATOLOGY, cilt.198, sa.6, ss.988-993, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 198 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1111/bjh.18233
  • Dergi Adı: BRITISH JOURNAL OF HAEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.988-993
  • Anahtar Kelimeler: relapsed or refractory multiple myeloma, proteasome inhibitor, carfilzomib, cytogenetics, CARFILZOMIB, DEXAMETHASONE
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.